Pediatric Hodgkin lymphoma: Trade-offs between short- and long-term mortality risks

Blood

Volumn 120, Issue 11, 2012, Pages 2195-2202

  Yeh, Jennifer M ^a   Diller, Lisa ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; DISEASE COURSE; HODGKIN DISEASE; LIFE EXPECTANCY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 84866338103     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-02-409821     Document Type: Article

References (34)

1. Ries LAG, Smith MA, Gurney JG, et al. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995 (NIH publication no. 99-4649). Bethesda, MD: National Cancer Institute, SEER Program; 1999.
2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/ 1975-2008. Accessed June 1, 2011.
3. Eich HT, Kriz J, Muller RP. Evolution of radiation therapy within the German Hodgkin Study Group trials. J Natl Compr Canc Netw. 2011;9(9):1073-1080.
4. Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol. 2002; 20(18):3765-3771.
5. Ekert H, Ashley D. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy, by Nachman et al. J Clin Oncol. 2003; 21(6):1192; author reply 1192.
6. Hudson MM. Pediatric Hodgkin's therapy: time for a paradigm shift. J Clin Oncol. 2002;20(18):3755-3757.
7. Tukenova M, Diallo I, Hawkins M, et al. Long-term mortality from second malignant neoplasms in 5-year survivors of solid childhood tumors: temporal pattern of risk according to type of treatment. Cancer Epidemiol Biomarkers Prev. 2010; 19(3):707-715.
8. Tukenova M, Guibout C, Oberlin O, et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol. 2010;28(8):1308-1315.
9. Castellino SM, Geiger AM, Mertens AC, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood. 2011;117(6):1806-1816.
10. Goldie SJ, Goldhaber-Fiebert JD, Garnett GP. Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling. Vaccine. 2006;24(Suppl 3):S155-S163. (Pubitemid 44293024)
11. Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27(14):2328-2338.
12. Mertens AC, Liu Q, Neglia JP, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2008;100(19):1368-1379.
13. Metzger ML, Hudson MM, Krasin MJ, et al. Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patients. Cancer. 2010;116(18):4376-4384.
14. Centers for Disease Control and Prevention National Center for Health Statistics. CDC WONDER On-line Database, compiled from Compressed Mortality File CMF. 1968-1988, series 20, no. 2A, 2000 and CMF 1989-1998, series 20, no. 2009; 2E:2003.
15. Nguyen F, Rubino C, Guerin S, et al. Risk of a second malignant neoplasm after cancer in childhood treated with radiotherapy: correlation with the integral dose restricted to the irradiated fields. Int J Radiat Oncol Biol Phys. 2008;70(3):908-915. (Pubitemid 351199725)
16. Inskip PD, Curtis RE. New malignancies following childhood cancer in the United States, 1973-2002. Int J Cancer. 2007;121(10):2233-2240. (Pubitemid 47585603)
17. Briggs AH, Goeree R, Blackhouse G, O'Brien BJ. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making. 2002;22(4):290-308. (Pubitemid 34791317)
18. Arias E. United States Life Tables, 2004. National Vital Statistics Reports. 2007;56(9).
19. Gold MR, Siegel JE, Russel LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
20. Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365(3):203-212.
21. Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med. 2011;366(5):399-408.
22. Connors JM. Hodgkin's lymphoma: the great teacher. N Engl J Med. 2011;365(3):264-265.
23. Straus DJ. Chemotherapy alone for early-stage Hodgkin's lymphoma. N Engl J Med. 2012; 366(5):470-471.
24. Hess CF, Kortmann RD, Schmidberger H, Bamberg M. How relevant is secondary leukaemia for initial treatment selection in Hodgkin's disease? Eur J Cancer. 1994;30A(10):1441-1447. (Pubitemid 24343002)
25. Ng AK, Weeks JC, Mauch PM, Kuntz KM. Decision analysis on alternative treatment strategies for favorable-prognosis, early-stage Hodgkin's disease. J Clin Oncol. 1999;17(11):3577-3585. (Pubitemid 29517930)
26. Herbst C, Rehan FA, Brillant C, et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review. Haematologica. 2010;95(3):494-500.
27. Wolden S, Chen L, Kelly K, et al. Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma. A report from the Children's Oncology Group [published online ahead of print May 29, 2012]. J Clin Oncol. doi: 10.1200/JCO.2011.1241. 1819.
28. Keller F, Nachman J, Constine L. A phase III study for the treatment of children and adolescents with newly diagnosed low risk Hodgkin lymphoma (HL) [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):Abstract 767.
29. Campbell BA, Hornby C, Cunninghame J, et al. Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy. Ann Oncol. 2011;23(5):1259-1266.
30. O'Brien MM, Donaldson SS, Balise RR, Whittemore AS, Link MP. Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol. 2010;28(7):1232-1239.
31. Cardous-Ubbink MC, Heinen RC, Bakker PJ, et al. Risk of second malignancies in long-term survivors of childhood cancer. Eur J Cancer. 2007;43(2):351-362. (Pubitemid 46123988)
32. Cardous-Ubbink MC, Heinen RC, Langeveld NE, et al. Long-term cause-specific mortality among five-year survivors of childhood cancer. Pediatr Blood Cancer. 2004;42(7):563-573. (Pubitemid 38669743)
33. Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol. 2005; 23(30):7614-7620. (Pubitemid 46291825)
34. Hodgson DC, Hudson MM, Constine LS. Pediatric Hodgkin lymphoma: maximizing efficacy and minimizing toxicity. Semin Radiat Oncol. 2007; 17(3):230-242. (Pubitemid 46970823)